Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Payables (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Payables for 14 consecutive years, with $85631.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 93.8% year-over-year to $85631.0, compared with a TTM value of $85631.0 through Nov 2025, down 93.8%, and an annual FY2025 reading of $49252.0, down 96.31% over the prior year.
  • Payables was $85631.0 for Q4 2025 at CNBX Pharmaceuticals, up from $49252.0 in the prior quarter.
  • Across five years, Payables topped out at $1.7 million in Q3 2023 and bottomed at $49252.0 in Q3 2025.
  • Average Payables over 5 years is $777236.8, with a median of $454209.0 recorded in 2022.
  • The sharpest move saw Payables soared 353.95% in 2023, then tumbled 96.31% in 2025.
  • Year by year, Payables stood at $200449.0 in 2021, then skyrocketed by 123.14% to $447290.0 in 2022, then surged by 248.73% to $1.6 million in 2023, then decreased by 11.51% to $1.4 million in 2024, then plummeted by 93.8% to $85631.0 in 2025.
  • Business Quant data shows Payables for CNBX at $85631.0 in Q4 2025, $49252.0 in Q3 2025, and $1.4 million in Q2 2025.